While the number of glioblastoma treatments in the pipeline is good news for patients, accessing these trials can be difficult. One barrier to clinical trial enrollment for brain cancer patients is the requirement that they not undergo standard of care. Since families and physicians are eager to begin care promptly after a diagnosis, making patients aware of trial options is key.

To help improve enrolment, a UK charity called brainstrust, which provides personalized support to patients with brain tumors, partnered with myTomorrows, an organization that connects patients with clinical trials. The collaboration should expedite trial recruitment for these patients, said Will Jones, brainstrust’s chief executive officer.

“There are more trials than we can keep track of,” he told In Vivo. “This is now bigger than us.”

myTomorrows is a global organization that works with physicians, patients and the biopharma industry to educate patients and their families about treatment options. The organization streamlines the process of identifying and enrolling in an appropriate clinical trial and has a multilingual team of patient navigators with close ties to physician networks and patient advocacy groups and can quickly access patient’s medical records with consent to identify treatment and clinical trial options.

“We try to inform patients of a clinical trial as soon as possible, so that, for one, they do not start a treatment that would exclude them from a trial,” myTomorrows’ marketing leader Sarah Swain told In Vivo.

As Jones said, “having a patient navigator on hand when making treatment decisions is so important, because you don’t know what you don’t know.”

Glioblastoma Market Snapshot: Two Approvals In 2024 And A Rich Pipeline

More from Market Intelligence

More from In Vivo